



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration

CENTER FOR DRUG EVALUATION AND RESEARCH

Division of Quality Surveillance Assessment
Inspection Assessment Branch
10903 New Hampshire Avenue
Building #51, Room 4235
Silver Spring, MD 20993

EMAIL: karen.sego@fda.hhs.gov
TELEPHONE: (513) 679-2700 ext. 2164
FAX: (301) 847-8742

June 25, 2015

Vijay Garg, Joint Managing Director
IOL Chemicals & Pharmaceuticals, Ltd.
Trident Complex, Mansa Road
Village Fatehgarh Channa
Barnala, Punjab 148101
India

Reference: FEI: 3008232281


Dear Mr. Garg:

We are enclosing a copy of the establishment inspection report (EIR) for the inspection that the U.S. Food and Drug Administration (FDA) conducted at your premises located at Trident Complex, Mansa Road, Village Fatehgarh Channa, Barnala, Punjab, India on April 13 – 17, 2015. When the Agency concludes that an inspection is “closed” under 21 CFR 20.64(d)(3), it will release a copy of the EIR to the inspected establishment. This procedure is applicable to EIRs for inspections completed on or after April 1, 1997.

The Agency continually works to make its regulatory process and activities more transparent to the regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 CFR Part 20. This, however, does not preclude you from requesting additional information under FOIA.

If there is any question about the released information, feel free to contact me at the above address, email or phone number.

Sincerely,



Karen Gale Segó
Compliance Officer
Inspection Assessment Branch

Enclosure: EIR